Latest & greatest articles for depression

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on depression or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on depression and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for depression

181. Psychotherapy for major depressive disorder and generalized anxiety disorder: a health technology assessment

Psychotherapy for major depressive disorder and generalized anxiety disorder: a health technology assessment Psychotherapy for major depressive disorder and generalized anxiety disorder: a health technology assessment Psychotherapy for major depressive disorder and generalized anxiety disorder: a health technology assessment Health Quality Ontario Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation Health Quality Ontario. Psychotherapy for major depressive disorder and generalized anxiety disorder: a health technology assessment. Toronto: Health Quality Ontario (HQO). Ontario health technology assessment series; 17(15). 2017 Authors' conclusions Compared with usual care, treatment with CBT, interpersonal therapy, or supportive therapy significantly reduces depression symptoms posttreatment. CBT significantly reduces anxiety symptoms

2018 Health Technology Assessment (HTA) Database.

182. Depression

Depression Scottish Palliative Care Guidelines - Depression Scottish Palliative Care Guidelines search / / / Depression Depression Introduction Depression: is strongly and consistently associated with a poor quality of life. causes more reduction in role and social functioning than would be due to the physical illness alone. reduces physical functioning. is often associated with symptoms that are difficult to control. has a major impact on the patient’s family. Treatment of depression can (...) significantly improve quality of life and is as effective in palliative care as in other situations. Assessment All patients should be assessed for depression. Physical symptoms commonly associated with depression can be caused by physical illness or treatments so may be less helpful in establishing a diagnosis. These can include: weight/appetite change insomnia loss of energy psychomotor slowing loss of libido Depressive symptoms in palliative care patients include: greater severity of dysphoric mood

2018 Scottish Palliative Care Guidelines

183. Efficacy and Safety of Transcranial Direct Current Stimulation as an Add-on Treatment for Bipolar Depression: A Randomized Clinical Trial Full Text available with Trip Pro

Efficacy and Safety of Transcranial Direct Current Stimulation as an Add-on Treatment for Bipolar Depression: A Randomized Clinical Trial More effective, tolerable interventions for bipolar depression treatment are needed. Transcranial direct current stimulation (tDCS) is a novel therapeutic modality with few severe adverse events that showed promising results for unipolar depression.To determine the efficacy and safety of tDCS as an add-on treatment for bipolar depression.A randomized, sham (...) -controlled, double-blind trial (the Bipolar Depression Electrical Treatment Trial [BETTER]) was conducted from July 1, 2014, to March 30, 2016, at an outpatient, single-center academic setting. Participants included 59 adults with type I or II bipolar disorder in a major depressive episode and receiving a stable pharmacologic regimen with 17-item Hamilton Depression Rating Scale (HDRS-17) scores higher than 17. Data were analyzed in the intention-to-treat sample.Ten daily 30-minute, 2-mA, anodal-left

2018 EvidenceUpdates

184. MiR‐339 depresses cell proliferation via directly targeting S‐phase kinase‐associated protein 2 mRNA in lung cancer Full Text available with Trip Pro

MiR‐339 depresses cell proliferation via directly targeting S‐phase kinase‐associated protein 2 mRNA in lung cancer S-phase kinase-associated protein 2 (Skp2) takes great part in the development of multiple tumors. However, the post-transcriptional modulation mechanism of Skp2 remains unclear. Here, we present a new regulatory microRNA of Skp2, miR-339, which directly targets Skp2 to inhibit cell proliferation in lung cancer.The expression of miR-339 or Skp2 in lung cancer samples (...) proliferation in lung cancer. Overexpressed Skp2 accelerated miR-339-bated proliferation of lung cancer cells. MiR-339 inhibitor promoted cell proliferation in lung cancer, but Skp2 RNA interference reversed miR-339 inhibitor-driven cell proliferation.MiR-339 targets the 3'-untranslated region of Skp2 mRNA to depress the proliferation of lung cancer cells.© 2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

2018 Thoracic cancer

185. SSRIs for depression/heart failure patients? Not so fast

SSRIs for depression/heart failure patients? Not so fast SSRIs for depression/heart failure patients? Not so fast Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics SSRIs for depression/heart failure patients? Not so fast View/ Open Date 2017-09 Format Metadata Abstract This study should put to rest the practice (...) of starting SSRIs in depressed patients with heart failure in an attempt to affect CVD outcomes. PRACTICE CHANGER: Do not prescribe selective serotonin reuptake inhibitors to improve depression and reduce cardiovascular risk in patients with congestive heart failure. Stength of recommendation: B: Based on one large randomized controlled trial. URI Part of Citation Journal of Family Practice, 66(9) 2017: 564-567. Rights OpenAccess. This work is licensed under a Creative Commons Attribution-NonCommercial

2018 PURLS

186. Is the serum oxytocin level altered by treatment in rheumatoid arthritis patients complicated with depression? Full Text available with Trip Pro

Is the serum oxytocin level altered by treatment in rheumatoid arthritis patients complicated with depression? The objective of this study was to investigate the factors associated with depression, including serum oxytocin (OXT) levels, disease activity, activities of daily living (ADL), and quality of life (QOL), and their effects on rheumatoid arthritis (RA).This study included 42 RA patients who received treatment with a biological agent. We measured the following variables before and after (...) 6 months of treatment: baseline characteristics, including age, sex, disease duration, smoking, and body mass index (BMI); prednisolone and methotrexate dose; serum level of matrix metalloproteinase-3 (MMP-3); erythrocyte sedimentation rate (ESR); and C-reactive protein (CRP) level. The disease activity of RA was assessed using the Simplified Disease Activity Index (SDAI); depression was assessed using the Hamilton Depression Rating Scale (HAM-D); ADL was assessed using the Health Assessment

2018 European journal of rheumatology

187. A study on characteristics of rheumatoid arthritis patients achieving remission in depression with 6 months of bDMARDs treatment Full Text available with Trip Pro

A study on characteristics of rheumatoid arthritis patients achieving remission in depression with 6 months of bDMARDs treatment To investigate the relationship between baseline factors and depression remission after a 6-month biological disease-modifying antirheumatic drugs (bDMARDs) treatment in rheumatoid arthritis (RA) patients.The study was conducted in 152 RA patients treated with bDMARDs. The following patient's characteristics were studied: gender, age, disease duration, baseline (...) prednisolone dosage, and serum matrix metalloproteinase3 (MMP3) levels. For assessment, we used the simple disease activity index (SDAI) for RA disease activity, Health Assessment Questionnaire Disability Index (HAQ-DI) for activities of daily living (ADL), Short Form-36 for nonspecific health-related quality of life (QOL), and Hamilton Depression Rating Scale (HAM-D) scores for the depression status. Depressed remission was clarified using HAM-D ≤7 after 6 months of treatment. The patients were divided

2018 European journal of rheumatology

188. Contraceptives as possible risk factors for postpartum depression: A retrospective study of the food and drug administration adverse event reporting system, 2004–2015 Full Text available with Trip Pro

Contraceptives as possible risk factors for postpartum depression: A retrospective study of the food and drug administration adverse event reporting system, 2004–2015 Postpartum depression is a mood disorder that commonly affects women during the early postpartum period. The objective of this study was to analyse the association of postpartum depression with drugs (including contraceptive devices and implants) with spontaneously reported adverse events reported in the US Food and Drug (...) Administration Adverse Event Reporting System database.Retrospective study.Reports of postpartum depression events between 2004-2015 were analysed with a reporting odds ratio (ROR) algorithm. The Medical Dictionary for Regulatory Activities was used to identify postpartum depression.The reporting odds ratios (95% confidence intervals, CI) of levonorgestrel (an intrauterine device with progestogen), etonogestrel (a hormonal contraceptive implant), sertraline and drospirenone (an oral contraceptive) were 12.5

2018 Nursing open

189. Regulations and legislation to reduce discrimination for people with depression, anxiety or who experience suicidality

Regulations and legislation to reduce discrimination for people with depression, anxiety or who experience suicidality Regulations and legislation to reduce discrimination for people with depression, anxiety or who experience suicidality Regulations and legislation to reduce discrimination for people with depression, An Evidence Check rapid review brokered by the Sax Institute for Beyond Blue. December 2018. An Evidence Check rapid review brokered by the Sax Institute 2 REGULATIONS (...) indicated above requires written permission from the copyright owners. Enquiries regarding this report may be directed to the: Principal Analyst Knowledge Exchange Program Sax Institute www.saxinstitute.org.au knowledge.exchange@saxinstitute.org.au Phone: +61 2 91889500 Suggested Citation: Stratton E, Glozier N. Regulations and legislation to reduce discrimination for people with depression, anxiety or who experience suicidality: an Evidence Check rapid review brokered by the Sax Institute

2018 Sax Institute Evidence Check

190. Depression and anxiety programs for children and young people

Depression and anxiety programs for children and young people Depression and anxiety programs for children and young people An Evidence Check rapid review brokered by the Sax Institute for Beyond Blue. December 2018. An Evidence Check rapid review brokered by the Sax Institute for Beyond Blue. December 2018 This report was prepared by: Skvarc D, Varcoe J, Reavley N, Rowland B, Jorm A, Toumbourou JW December 2018 © Sax Institute 2018 This work is copyright. It may be reproduced in whole (...) , Reavley N, Rowland B, Jorm A, Toumbourou JW. Depression and anxiety programs for children and young people: an Evidence Check rapid review brokered by the Sax Institute (www.saxinstitute.org.au) for the Beyond Blue 2018. Disclaimer: This Evidence Check Review was produced using the Evidence Check methodology in response to specific questions from the commissioning agency. It is not necessarily a comprehensive review of all literature relating to the topic area. It was current at the time of production

2018 Sax Institute Evidence Check

191. Prevention and early intervention for adults with mild to moderate depression

Prevention and early intervention for adults with mild to moderate depression Prevention and early intervention for adults with mild to moderate depression d An Evidence Check rapid review brokered by the Sax Institute for Beyond Blue. December 2018. An Evidence Check rapid review brokered by the Sax Institute for Beyond Blue. December 2018. This report was prepared by: Frances Kay-Lambkin, Jayden Gilbert, Lauren Pedemont, Matthew Sunderland, Hazel Dalton, Tonelle Handley, Sally Chan, David (...) @saxinstitute.org.au Phone: +61 2 91889500 Suggested Citation: Kay-Lambkin F, Gilbert J, Pedemont L, Sunderland M, Dalton H et al. Prevention and early intervention for people aged 18 and over with, or at risk of, mild to moderate depression and anxiety: An Evidence Check rapid review brokered by the Sax Institute (www.saxinstitute.org.au) for Beyond Blue, 2018. Disclaimer: This Evidence Check Review was produced using the Evidence Check methodology in response to specific questions from the commissioning agency

2018 Sax Institute Evidence Check

192. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders: major depression summary

Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders: major depression summary Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders: major depression summary | The Medical Journal of Australia mja-search search Use the for more specific terms. Title contains Body contains Date range from Date range to Article type Author's surname Volume First page doi: 10.5694/mja__.______ Search Reset (...)  close Individual Login Purchase options Connect person_outline Login keyboard_arrow_down Individual Login Purchase options menu search Advertisement close Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders: major depression summary Gin S Malhi, Tim Outhred, Amber Hamilton, Philip M Boyce, Richard Bryant, Paul B Fitzgerald, Bill Lyndon, Roger Mulder, Greg Murray, Richard J Porter, Ajeet B Singh and Kristina Fritz Med J Aust 2018; 208 (4

2018 MJA Clinical Guidelines

193. Internet-Delivered Cognitive Behavioural Therapy for Major Depression and Anxiety Disorders: A Review of Clinical Effectiveness

Internet-Delivered Cognitive Behavioural Therapy for Major Depression and Anxiety Disorders: A Review of Clinical Effectiveness Internet-Delivered Cognitive Behavioural Therapy for Major Depression and Anxiety Disorders: A Review of Clinical Effectiveness | CADTH.ca Find the information you need Internet-Delivered Cognitive Behavioural Therapy for Major Depression and Anxiety Disorders: A Review of Clinical Effectiveness Internet-Delivered Cognitive Behavioural Therapy for Major Depression (...) and Anxiety Disorders: A Review of Clinical Effectiveness Last updated: September 5, 2018 Project Number: RC1011-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of internet-delivered cognitive behavioural therapy for patients with mild to moderate major depression or anxiety disorders? Key Message Nine randomized controlled trials were identified regarding the clinical effectiveness of iCBT

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

194. Antidepressants for Adults with Depression using Opioid Medications: Clinical Effectiveness and Guidelines

Antidepressants for Adults with Depression using Opioid Medications: Clinical Effectiveness and Guidelines Antidepressants for Adults with Depression using Opioid Medications: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Antidepressants for Adults with Depression using Opioid Medications: Clinical Effectiveness and Guidelines Antidepressants for Adults with Depression using Opioid Medications: Clinical Effectiveness and Guidelines Last updated: February 16 (...) , 2018 Project Number: RB1196-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of antidepressants in adults with depression using opioid medications? What are the evidence-based guidelines informing the use of antidepressants in adults with depression using opioid medications? Key Message Two systematic reviews, one meta-analysis, four randomized controlled trials, and one evidence-based guideline was identified

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

195. Telehealth for the Assessment and Treatment of Depression, Post-Traumatic Stress Disorder, and Anxiety: Clinical Evidence

Telehealth for the Assessment and Treatment of Depression, Post-Traumatic Stress Disorder, and Anxiety: Clinical Evidence Telehealth for the Assessment and Treatment of Depression, Post-Traumatic Stress Disorder, and Anxiety: Clinical Evidence | CADTH.ca Find the information you need Telehealth for the Assessment and Treatment of Depression, Post-Traumatic Stress Disorder, and Anxiety: Clinical Evidence Telehealth for the Assessment and Treatment of Depression, Post-Traumatic Stress Disorder (...) , and Anxiety: Clinical Evidence Last updated: April 10, 2018 Project Number: RC0980-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of psychological assessment delivered via telehealth for patients with depression, post-traumatic stress disorder, or anxiety? What is the clinical effectiveness of psychological treatment delivered via telehealth for patients with depression, post-traumatic stress

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

196. Policies to Reduce Harms from the Concomitant Use of Opioids and Central Nervous System Depressant Drugs

Policies to Reduce Harms from the Concomitant Use of Opioids and Central Nervous System Depressant Drugs Policies to Reduce Harms from the Concomitant Use of Opioids and Central Nervous System Depressant Drugs | CADTH.ca Find the information you need Policies to Reduce Harms from the Concomitant Use of Opioids and Central Nervous System Depressant Drugs Policies to Reduce Harms from the Concomitant Use of Opioids and Central Nervous System Depressant Drugs Last updated: July 9, 2018 Project (...) Number: ES0324-000 Product Line: Result type: Report Patients who are prescribed opioids may also be treated for conditions requiring the use of tranquilizing drugs, such as benzodiazepines, that function as central nervous system depressants. Concurrent use of these two types of drugs has been associated with an increased risk of harms including injuries, overdose, and death. To protect patients from these harms, policies and other concerted efforts have been implemented by local and international

2018 Canadian Agency for Drugs and Technologies in Health - Environmental Scanning

197. Internet-Delivered Cognitive Behavioural Therapy for Major Depressive Disorder and Anxiety Disorders: An Environmental Scan

Internet-Delivered Cognitive Behavioural Therapy for Major Depressive Disorder and Anxiety Disorders: An Environmental Scan Internet-Delivered Cognitive Behavioural Therapy for Major Depressive Disorder and Anxiety Disorders: An Environmental Scan | CADTH.ca Find the information you need Internet-Delivered Cognitive Behavioural Therapy for Major Depressive Disorder and Anxiety Disorders: An Environmental Scan Internet-Delivered Cognitive Behavioural Therapy for Major Depressive Disorder (...) and Anxiety Disorders: An Environmental Scan Last updated: September 21, 2018 Project Number: ES0331-000 Product Line: Result type: Report CADTH is conducting an Environmental Scan to better understand the breadth of Internet-delivered cognitive behavioural therapy (iCBT) programs offered across Canada and to identify facilitators and barriers to implementation across Canada. The objectives of this Environmental Scan are: to identify existing or developing iCBT programs for major depressive disorder

2018 Canadian Agency for Drugs and Technologies in Health - Environmental Scanning

198. Guided Versus Unguided Internet-Delivered Cognitive Behavioural Therapy for Major Depressive Disorder and Anxiety Disorders: Comparative Clinical Effectiveness

Guided Versus Unguided Internet-Delivered Cognitive Behavioural Therapy for Major Depressive Disorder and Anxiety Disorders: Comparative Clinical Effectiveness Guided Versus Unguided Internet-Delivered Cognitive Behavioural Therapy for Major Depressive Disorder and Anxiety Disorders: Comparative Clinical Effectiveness | CADTH.ca Find the information you need Guided Versus Unguided Internet-Delivered Cognitive Behavioural Therapy for Major Depressive Disorder and Anxiety Disorders: Comparative (...) Clinical Effectiveness Guided Versus Unguided Internet-Delivered Cognitive Behavioural Therapy for Major Depressive Disorder and Anxiety Disorders: Comparative Clinical Effectiveness Last updated: October 29, 2018 Project Number: RB1269-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the comparative clinical effectiveness of guided versus unguided internet-delivered cognitive behavioural therapy for patients with mild

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

199. e-Therapy Interventions for the Treatments of Patients with Depression: A Review of Clinical Effectiveness

e-Therapy Interventions for the Treatments of Patients with Depression: A Review of Clinical Effectiveness e-Therapy Interventions for the Treatments of Patients with Depression: A Review of Clinical Effectiveness | CADTH.ca Find the information you need e-Therapy Interventions for the Treatments of Patients with Depression: A Review of Clinical Effectiveness e-Therapy Interventions for the Treatments of Patients with Depression: A Review of Clinical Effectiveness Last updated: May 18, 2018 (...) Project Number: RC0983-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of e-therapy for the treatment of patients with depression? Key Message Evidence from a small number of systematic reviews (SRs) and small size randomized controlled trials (RCTs) consistently showed that therapist-guided e-therapy was superior to no treatment, wait list, or TAU in reducing depressive symptoms

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

200. Alterations in Systemic and Cognitive Glucocorticoid Sensitivity in Depression. Full Text available with Trip Pro

Alterations in Systemic and Cognitive Glucocorticoid Sensitivity in Depression. Decades of research point to cortisol insensitivity as a biomarker of depression. Despite a vast literature on cortisol's effects on memory, the role of cortisol insensitivity in core psychological features of depression, such as emotional memory biases, is unknown.Sixty-five premenopausal women with varying levels of depression completed this study involving an at-home low-dose dexamethasone suppression test (...) placebo administration.Cortisol insensitivity was associated with more severe depression and flatter diurnal cortisol levels. Cortisol insensitivity predicted negative memory bias for pictures encoded during the placebo session and reduction in negative memory bias for pictures encoded during the CORT (compared with placebo) session, even after accounting for psychiatric symptomatology.Our findings replicate research showing that cortisol insensitivity predicts depression severity and flatter diurnal

2018 Biological psychiatry. Cognitive neuroscience and neuroimaging Controlled trial quality: uncertain